ATNM's first 3 patients had no problems that stopped dose increases, and scans showed the drug stayed in tumors through Day 7. This supports an encouraging early read, but the small group and no reported patient response results mean treatment benefit is not yet shown.
That gives ATNM an early sign that the treatment can be given and reaches tumors. But the safety finding covers only 3 patients, and the report gives no patient response results. The trial is still testing higher doses, so it has not yet shown that patients benefit.
Follow Actinium Pharmaceuticals Inc. (ATNM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ATNM